Hydreight Achieves 33% YoY H1 Revenue Growth, Records 3rd Consecutive Quarter of Profitability, and Strengthens Performance Across Verticals
Hydreight Technologies (OTCQB:HYDTF), a mobile clinical network and medical platform, reported strong financial results for Q2 2025, marking its third consecutive quarter of profitability. The company achieved Q2 GAAP revenue of $5.38 million, up 31% year-over-year, and H1 2025 revenue of $9.92 million, representing a 33% increase.
Key performance metrics include Q2 Gross Margin of $1.93 million, Adjusted EBITDA of $182K, and GAAP Net Income of $50K. The company saw significant growth with a 77% increase in new nurse signups and 48% growth in pharmacy orders compared to Q2 2024.
Hydreight announced a strategic initiative to acquire a 5% equity stake in Perfect Scripts, LLC with an option to increase to 40%, and launched a C$10 Million Convertible Debenture Offering to support growth and M&A activities.
Hydreight Technologies (OTCQB:HYDTF), rete clinica mobile e piattaforma medica, ha riportato risultati finanziari solidi per il secondo trimestre 2025, segnando il suo terzo trimestre consecutivo in utile. La società ha realizzato ricavi GAAP del Q2 pari a $5,38 milioni, in aumento del 31% su base annua, e ricavi per il primo semestre 2025 di $9,92 milioni, con un incremento del 33%.
I principali indicatori includono un margine lordo Q2 di $1,93 milioni, un EBITDA rettificato di $182K e un utile netto GAAP di $50K. La società ha registrato una crescita significativa con un aumento del 77% delle nuove iscrizioni di infermieri e una crescita del 48% negli ordini di farmacia rispetto al Q2 2024.
Hydreight ha annunciato un'iniziativa strategica per acquisire una quota azionaria del 5% in Perfect Scripts, LLC con opzione di incremento fino al 40% e ha lanciato un offerta di cambiali convertibili da C$10 milioni per sostenere la crescita e le attività di M&A.
Hydreight Technologies (OTCQB:HYDTF), una red clínica móvil y plataforma médica, informó sólidos resultados financieros para el segundo trimestre de 2025, marcando su tercer trimestre consecutivo de rentabilidad. La compañía alcanzó ingresos GAAP en Q2 de $5.38 millones, un aumento del 31% interanual, y ingresos en el primer semestre de 2025 de $9.92 millones, un 33% más.
Los indicadores clave incluyen un margen bruto en Q2 de $1.93 millones, EBITDA ajustado de $182K y utilidad neta GAAP de $50K. La empresa experimentó un crecimiento notable con un aumento del 77% en nuevas inscripciones de enfermeras y un crecimiento del 48% en pedidos de farmacia respecto al Q2 de 2024.
Hydreight anunció una iniciativa estratégica para adquirir una participación del 5% en Perfect Scripts, LLC con opción de aumentar hasta el 40%, y lanzó una oferta de pagarés convertibles por C$10 millones para apoyar el crecimiento y actividades de fusiones y adquisiciones.
Hydreight Technologies (OTCQB:HYDTF), 모바� 임상 네트워크 � 의료 플랫폼은 2025� 2분기 강력� 실적� 발표하며 3분기 연속 흑자 기록� 이어갔습니다. 회사� 2분기 GAAP 매출 $5.38M� 달성� 전년 동기 대� 31% 증가했으�, 2025� 상반� 매출은 $9.92M으로 33% 증가했습니다.
주요 성과 지표로� 2분기 총이� $1.93M, 조정 EBITDA $182K, GAAP 당기순이� $50K가 포함됩니�. 신규 간호� 가입이 77% 증가했고, 약국 주문은 전년 동기 대� 48% 성장하는 � 의미 있는 성장� 보였습니�.
ٵ� Perfect Scripts, LLC 지� 5% 인수� 위한 전략� 계획� 발표했으� 최대 40%까지 확대� � 있는 옵션� 보유하고, 성장� M&A 활동� 지원하� 위해 캐나� 달러 C$1,000� 규모� 전환사채 공모� 시작했습니다.
Hydreight Technologies (OTCQB:HYDTF), réseau clinique mobile et plateforme médicale, a publié de solides résultats financiers pour le deuxième trimestre 2025, marquant son troisième trimestre consécutif de rentabilité. La société a réalisé un chiffre d'affaires GAAP au T2 de 5,38 M$, en hausse de 31% en glissement annuel, et un chiffre d'affaires pour le premier semestre 2025 de 9,92 M$, soit une augmentation de 33%.
Les indicateurs clés comprennent un marge brute T2 de 1,93 M$, un EBITDA ajusté de 182 K$ et un résultat net GAAP de 50 K$. L'entreprise a connu une croissance notable avec une augmentation de 77% des nouvelles inscriptions d'infirmières et une hausse de 48% des commandes pharmaceutiques par rapport au T2 2024.
Hydreight a annoncé une initiative stratégique visant à acquérir une participation de 5% dans Perfect Scripts, LLC avec une option d'extension jusqu'à 40%, et a lancé une offre d'obligations convertibles de 10 M$ CA pour soutenir la croissance et les opérations de fusion-acquisition.
Hydreight Technologies (OTCQB:HYDTF), ein mobiles klinisches Netzwerk und medizinische Plattform, meldete starke Finanzergebnisse für das 2. Quartal 2025 und verzeichnet damit sein drittes aufeinanderfolgendes profitables Quartal. Das Unternehmen erzielte Q2-GAAP-Umsatz von $5,38 Mio., ein Plus von 31% gegenüber dem Vorjahr, und Halbjahresumsatz 2025 von $9,92 Mio., ein Anstieg um 33%.
Wesentliche Kennzahlen sind ein Bruttogewinn Q2 von $1,93 Mio., ein bereinigtes EBITDA von $182K und ein GAAP-Nettogewinn von $50K. Das Unternehmen verzeichnete erhebliches Wachstum mit einem 77%igen Anstieg neuer Krankenschwestern-Anmeldungen und einem 48%igen Zuwachs bei Apothekenbestellungen gegenüber Q2 2024.
Hydreight kündigte eine strategische Initiative zur Übernahme einer 5%igen Beteiligung an Perfect Scripts, LLC mit Option auf Ausbau bis 40% an und startete ein Wandeldarlehensangebot über C$10 Millionen zur Unterstützung von Wachstum und M&A-Aktivitäten.
- 33% year-over-year revenue growth in first 6 months of 2025
- Third consecutive quarter of profitability with Q2 Net Income of $50K
- 77% growth in new Nurse signup compared to Q2 2024
- 48% growth in Number of pharmacy orders year-over-year
- Strong cash position with $6.10 million on hand at quarter-end
- Strategic expansion through Perfect Scripts acquisition opportunity
- 16% decline in Adjusted EBITDA from $218K in Q2 2024 to $182K in Q2 2025
- Taking on debt through $10M convertible debenture offering after historically avoiding debt
- Extension needed for Perfect Scripts definitive agreement deadline
“We had a great first 6 months, with
VANCOUVER, British Columbia and LAS VEGAS, Aug. 25, 2025 (GLOBE NEWSWIRE) -- (�Hydreight� or the “Cdz貹Բ�) ()()(), a mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is pleased to announce its financial results for the second quarter ended June 30, 2025. All financial information is presented in Canadian dollars unless otherwise indicated.
Q2 2025 Highlights
- Q2, 2025 GAAP revenue was
$5.38 million an increase of31% compared to Q2, 2024. - Q2, 2025 topline¹ record revenue of
$7.35 million , an increase of31% compared to Q2, 2024. - First 6 months GAAP revenue was
$9.92 million an increase of33% compared to the same period last year. - First 6 months topline¹ revenue was
$13.88 million an increase of33% compared to the same period last year. - Gross Margin of
$1.93 million , up from$1.56 million in Q2 2024 - Adjusted EBITDA¹ of
$182 K for Q2 2025, marking continued operational improvement - GAAP Net Income of 50K, from GAAP Net Loss of
$27 K in Q2, 2024 - Cash on Hand of
$6.10 million at quarter-end - Approximately
77% growth in new Nurse signup compared to Q2, 2024 - Approximately
48% growth in Number of pharmacy orders compared to Q2, 2024 - The Company’s internal matrix for VSDHOne SKU orders between June and the end of August was approximately 70,000�80,000 SKUs. Within the first 60 days of that period, the Company has already received approximately 42,829 pharmacy SKU orders and with the momentum in August is on track to fulfill and surpass the entire period goal.
- Launches Personalized Genetic Testing and Wellness Solution on VSDHOne Platform
- The Company has shared its story at multiple investor conferences and will continue this outreach in Q3 and throughout the year.
- In 2025, the Company received unpaid analyst coverage from firms including Maxim Group and Beacon Securities, and will continue pursuing additional high-quality coverage throughout the year and beyond.
- Hydreight Technologies Signed Binding Letter of Intent to Acquire
5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to40% , and Establish Strategic Partnership - Hydreight Technologies will host a live earnings call to discuss its Q2, 2025 results, provide a business update, and share insights into the Company’s strategic priorities for 2025.
Shane Madden, CEO of Hydreight, commented: “As we entered Q2, we set clear strategic goals, and I’m pleased to report we’ve either achieved them or made significant progress. We remained focused on growth across all three verticals while delivering profitability and sustaining positive Adjusted EBITDA. We also expanded into genetic testing, anti-aging, and mental wellness—broadening our reach and value to patients. At the same time, we’ve advanced the onboarding of high-volume franchise and direct-to-consumer partners, while pursuing tuck-in M&A opportunities that strengthen both revenue and margins. These milestones position us strongly for the remainder of 2025 and beyond.�
Highlights and Subsequent Events
- On May 27, 2025,
- On May 5, 2025,
- On May 1, 2025,
- On April 17, 2025,
- On April 15, 2025,
- On April 8, 2025,
- On April 2, 2025,
- On February 27, 2025,
- On February 26, 2025,
- On February 19, 2025,
- On February 18, 2025,
- On February 10, 2025,
- On February 5, 2025,
- On January 29, 2025,
- On January 21, 2025,
- On January 9, 2025,
The Company believes the following Non-GAAP1 financial measures provide meaningful insight to aid in the understanding of the Company’s performance and may assist in the evaluation of the Company’s business relative to that of its peers:
Three months ended June 30, | Six months ended June 30, | ||||||||||||
2025 | 2024 | % change | 2025 | 2024 | % change | ||||||||
Adjusted Revenue | $ | 7,348,796 | $ | 5,589,481 | $ | 13,876,753 | $ | 10,456,485 | |||||
Deduct - deferred business partner contract revenue | 198,794 | (186,935 | ) | 652,934 | (303,913 | ) | |||||||
Deduct - business partner payouts on app service gross revenue | 1,773,483 | 1,676,204 | 3,307,178 | 3,282,580 | |||||||||
GAAP Revenue | $ | 5,376,519 | $ | 4,100,212 | $ | 9,916,641 | $ | 7,477,818 | |||||
Adjusted Gross Margin | $ | 2,128,996 | $ | 1,372,862 | $ | 4,087,601 | $ | 2,487,218 | |||||
Deduct - deferred business partner contract revenue | 198,794 | (186,935 | ) | 652,934 | (303,913 | ) | |||||||
GAAP Gross Margin | $ | 1,930,202 | $ | 1,559,797 | $ | 3,434,667 | $ | 2,791,131 | |||||
Adjusted EBITDA | $ | 181,971 | $ | 217,708 | - | $ | 345,383 | $ | 171,835 | ||||
Deduct - amortization and depreciation | 107,129 | 24,636 | 208,133 | 71,189 | |||||||||
Deduct - share-based payments | 24,975 | 220,159 | 66,480 | 436,454 | |||||||||
GAAP Net Income (Loss) | $ | 49,867 | $ | (27,087 | ) | $ | 70,770 | $ | (335,808 | ) |
1 Refer to Use of Non-GAAP Financial Measures
The table below sets out a summary of certain financial results of the Company over the past eight quarters and is derived from the audited annual consolidated financial statements and unaudited quarterly consolidated financial statements of the Company.
Fiscal Quarter Ended | Revenue | Net Income (Loss) After Taxes | Comprehensive Income (Loss) | Basic Income (Loss) Per Share | Diluted Income (Loss) Per Share | |||||
June 30, 2025 | 5,376,519 | 49,867 | 160,779 | 0.00 | 0.00 | |||||
March 31, 2025 | 4,540,122 | 20,903 | 21,652 | 0.00 | 0.00 | |||||
December 31, 2024 | 4,040,578 | 20,577 | (106,396 | ) | 0.00 | 0.00 | ||||
September 30, 2024 | 4,526,320 | (89,938 | ) | (53,119 | ) | (0.00 | ) | (0.00 | ) | |
June 30, 2024 | 4,100,212 | (27,087 | ) | (48,184 | ) | (0.00 | ) | (0.00 | ) | |
March 31, 2024 | 3,377,606 | (308,721 | ) | (370,559 | ) | (0.01 | ) | (0.01 | ) | |
December 31, 2023 | 3,373,193 | (898,561 | ) | (865,068 | ) | (0.02 | ) | (0.02 | ) | |
September 30, 2023 | 3,088,219 | (466,973 | ) | (548,954 | ) | (0.01 | ) | (0.01 | ) |
Please see + for the Company's condensed consolidated audited financial statements and MD&A for audited annual consolidated financial statements for the year ended December 31, 2023.
The Company has experienced dramatic user growth over the past two years as can be seen by the consistent revenue growth over the past eight quarters. Net loss and comprehensive loss have generally remained comparable from the fourth quarter of 2021 through the current period when looking only at operating expenses, not including the RTO Transaction related expenses included in the fourth quarter of 2022.
️Upcoming Earnings Call
Hydreight Technologies will host a live earnings call to discuss its Q2, 2025 results, provide a business update, and share insights into the Company’s strategic priorities for 2025.
Date & Time: Wednesday, August 27th, 2025 at 10:45 - 11:15
Registration Link:
The event will include a formal presentation followed by a Q&A session with investors.
Launching C
On August 18, 2025, Hydreight announced up to
“We’ve always prioritized being fiscally responsible—funding our growth without taking on debt. While we could already achieve positive net profit and maintain strong cash reserves, we saw an opportunity to accelerate our goals with major investments and strategic M&A. To support this growth, diversify our institutional investor base, and align with partners who believe in our long-term vision, we made the decision to launch this initiative.� � Shane Madden, CEO of Hydreight
Capital Markets and Investment Conference Activities:
Hydreight will be participating in multiple capital markets and investment conferences to share its story with both existing and new investors. This strategy will continue in Q3 and throughout the remainder of the year.
Upcoming Investor Conferences:
CEM Muskoka Capital Event
Date: September 26�28, 2025
Location: Muskoka, ON
Conference Info:
Smallcap Discoveries Investor Event
Date: September 29�30, 2025
Location: Vancouver, BC
Conference Info:
Planet Microcap Showcase in partnership with MicroCapClub
Date: October 21-23, 2025
Location: Toronto, Ontario
Conference Info:
The Company also announces that, further to its news release dated July 14, 2025, the Company and Perfect Scripts LLC have mutually agreed to extend the deadline to draft, finalize and execute a definitive agreement (the �Definitive Agreement�) respecting their proposed strategic partnership transaction (the �Transaction�) from August 25, 2025 to September 3, 2025. Closing of the Transaction would occur within five business days of the date of the Definitive Agreement or such earlier or later date as the parties may agree or the TSX Venture Exchange may require. The completion of the Transaction remains subject to the fulfillment or waiver of several conditions, including receipt by Hydreight of approval from the TSX Venture Exchange.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Contact
Email:;Telephone: (702) 970-8112
Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the
Hydreight Technologies Recognized as a
This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
About Hydreight Technologies Inc.
Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 200 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
About VSDHOne - Direct to Consumer Platform
Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT�), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Use of Non-GAAP Financial Measures:
This release contains references to non-GAAP financial measures Adjusted Revenue, Adjusted Gross Margin and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustment for the deferred portion of business partner contract revenue and gross receipts from Hydreight App service sales. The Company defines Adjusted Gross Margin as GAAP gross margin plus inventory impairment plus the deferred portion of business partner contract revenue. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance. The Company believes that the measures provide information useful to its shareholders and investors in understanding the Company’s operating cash flow growth, user growth, and cash generating potential and may assist in the evaluation of the Company’s business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information� within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may�, “would�, “could�, “should�, “will�, “intend�, “plan�, “anticipate�, “believe�, “estimate�, “expect� or similar expressions and includes information regarding expectations for the 2025 strategic outlook, Company's growth, Margins and VSDHOne’s and Hydreight’s growth and numbers in 2025 and month of August 2025.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
¹See Use of Non-GAAP Financial Measures
